PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31369842-0	2019	Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats.	Metformin	79-88	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	93-97	
31369842-11	2019	Linagliptin and metformin were synergistical to target AMPK/Nox4 signal pathway in VSMCs incubated with HG and in the cardia artery of diabetic rats, which was superior to the monotherapy.	Metformin	16-25	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	55-59	
31369842-12	2019	CONCLUSIONS: We demonstrated that the potential protection of the combined use of linagliptin and metformin on VSMC remodeling through AMPK/Nox4 signal pathway, resulting in the improvement of neointima hyperplasia in diabetic rats.	Metformin	98-107	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	135-139